help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Published ahead of print on January 25, 2007, doi:10.1164/rccm.200610-1436CP
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
200610-1436CPv1
175/8/763    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McCall, C. E.
Right arrow Articles by Yoza, B. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McCall, C. E.
Right arrow Articles by Yoza, B. K.
American Journal of Respiratory and Critical Care Medicine Vol 175. pp. 763-767, (2007)
© 2007 American Thoracic Society
doi: 10.1164/rccm.200610-1436CP


Critical Care Perspective

Gene Silencing in Severe Systemic Inflammation

Charles E. McCall1 and Barbara K. Yoza1,2

1 Sections of Molecular Medicine and Infectious Diseases, Department of Internal Medicine, and 2 Division of Surgical Sciences, Department of General Surgery, Wake Forest University School of Medicine, Winston-Salem, North Carolina

Correspondence and requests for reprints should be addressed to Charles E. McCall, M.D., Section of Molecular Medicine, Department of Medicine, Wake Forest University School of Medicine, Winston-Salem, NC 27157-1042. E-mail: chmccall{at}wfubmc.edu

ABSTRACT

This critical care perspective appraises reprogramming of gene expression in inflammatory diseases as an emerging concept of clinical importance. We emphasize gene reprogramming that "silences" acute proinflammatory genes during severe systemic inflammation, wherein in the systemic inflammatory response syndrome (SIRS) exists as a continuum during severe sepsis, septic shock, and the multiorgan dysfunction and failure phenotypes without infection. In contrast, silencing of acute proinflammatory genes is not apparent in sites of localized inflammatory processes like rheumatoid arthritis. We discuss in three parts the clinical context and the translational basic science associated with gene silencing during the SIRS continuum of severe systemic inflammation: (1) reprogramming of acute proinflammatory genes; (2) a "nuclear factor-{kappa}B paradox," coupled with RelB expression, that combine to silence genes using an epigenetic (inherited and reversible) signature on the nucleosome; and (3) the potential clinical importance of compartmentalization in gene silencing. Our emergent understanding of these physiologic processes may provide a novel framework for developing treatments.

Key Words: compartmentalization • epigenetic • gene silencing • reprogramming




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
M. E. Gazzar, B. K. Yoza, X. Chen, J. Hu, G. A. Hawkins, and C. E. McCall
G9a and HP1 Couple Histone and DNA Methylation to TNF{alpha} Transcription Silencing during Endotoxin Tolerance
J. Biol. Chem., November 21, 2008; 283(47): 32198 - 32208.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. E. Gazzar, B. K. Yoza, J. Y.-Q. Hu, S. L. Cousart, and C. E. McCall
Epigenetic Silencing of Tumor Necrosis Factor {alpha} during Endotoxin Tolerance
J. Biol. Chem., September 14, 2007; 282(37): 26857 - 26864.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2007 American Thoracic Society
  ATS PAR News